Bose George

Henry Coffey

Fred Small

Brian Morrison

Mark Hammond

- Park Ha Biological Technology Co., Ltd. held its 2025 Annual General Meeting on **October 3, 2025**, where a quorum was reached with **21,872,753 ordinary shares** voted out of **33,874,403** issued and outstanding.  **[1986247_0001213900-25-097216_ea0260614-6k_parkha.htm:0]** 
- Shareholders approved an **increase in authorized share capital to US$300,000**, divided into **15,000,000,000 ordinary shares** of par value US$0.00002 each, which are re-classified into **12,000,000,000 Class A ordinary shares (1 vote per share)** and **3,000,000,000 Class B ordinary shares (20 votes per share)**.  **[1986247_0001213900-25-097216_ea0260614-6k_parkha.htm:1]** **[1986247_0001213900-25-097216_ea026061401ex3-1_parkha.htm:3]** 
- The existing **33,874,403 ordinary shares** were re-designated as Class A Ordinary Shares, and **19,050,000 Class A Ordinary Shares held by Xiaoqiu Zhang were surrendered for nil consideration and reissued as Class B Ordinary Shares**, concentrating voting power.  **[1986247_0001213900-25-097216_ea0260614-6k_parkha.htm:1]** 
- A share consolidation (reverse stock split) was approved, with a ratio from **one-for-five to one-for-thirty**, to be determined by the Board within one year.  **[1986247_0001213900-25-097216_ea0260614-6k_parkha.htm:1]**

Park Ha Biological Technology Co., Ltd. Approves Dual-Class Share Structure and Share Consolidation

- Park Ha Biological Technology Co., Ltd. reported a **45% increase** in total revenue to **$1,239,197** for the six months ended April 30, 2025, compared to $852,928 for the same period in 2024.  **[1986247_0001213900-25-080494_ea025446601ex99-1_parkha.htm:2]** **[1986247_0001213900-25-080494_ea025446601ex99-1_parkha.htm:3]**  However, the company recorded a **net loss of $19,835,994** for the period, a significant decline from a net income of $48,900 in the prior year, resulting in an **EPS of ($0.74)**.  **[1986247_0001213900-25-080494_ea025446601ex99-2_parkha.htm:1]** **[1986247_0001213900-25-080494_ea025446601ex99-1_parkha.htm:2]** 
- The substantial net loss was primarily attributed to a **4464% increase** in general and administrative expenses, which surged to **$20,632,549** for the six months ended April 30, 2025, largely driven by **$19,950,000** in share-based compensation expense.  **[1986247_0001213900-25-080494_ea025446601ex99-2_parkha.htm:1]** **[1986247_0001213900-25-080494_ea025446601ex99-1_parkha.htm:2]** **[1986247_0001213900-25-080494_ea025446601ex99-2_parkha.htm:2]** 
- Cash and cash equivalents increased to **$1,351,285** as of April 30, 2025, from $547,498 as of October 31, 2024, primarily due to **$3,833,511** in net cash provided by financing activities, mainly from the issuance of shares.  **[1986247_0001213900-25-080494_ea025446601ex99-2_parkha.htm:0]** **[1986247_0001213900-25-080494_ea025446601ex99-1_parkha.htm:7]** 
- The number of franchisees decreased to **39** as of April 30, 2025, from 43 as of April 30, 2024.  **[1986247_0001213900-25-080494_ea025446601ex99-1_parkha.htm:0]** **[1986247_0001213900-25-080494_ea025446601ex99-1_parkha.htm:4]**

Park Ha Biological Technology (PHH)